SCHEMBL10093029

SCHEMBL10093029

COC(=O)CN(C)C(=O)Cc1cc(Cl)ccc1Oc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 7/20 0.44
HTT P42858 1/20 0.44
LMNA P02545 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
SLC6A4 P31645 2/20 0.42
HTR2A P28223 1/20 0.42
KCNH2 Q12809 1/20 0.42
MAPT P10636 2/20 0.42
CHRM1 P11229 1/20 0.42
ALDH1A1 P00352 1/20 0.42
TP53 P04637 1/20 0.42
MAPK1 P28482 1/20 0.42
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13752339 0.93 L3MBTL1 (0.43) L3MBTL1HTTLMNASMN1; SMN2SLC6A4
SCHEMBL14636285 0.90 NPSR1 (0.44) L3MBTL1HTTLMNASMN1; SMN2SLC6A4
SCHEMBL872624 0.86 SLC6A4 (0.53) L3MBTL1SLC6A4HTR2AMAPTCHRM1
SCHEMBL967886 0.85 L3MBTL1 (0.51) L3MBTL1HTTLMNASMN1; SMN2SLC6A4
SCHEMBL13752342 0.80 L3MBTL1 (0.43) L3MBTL1HTTLMNASMN1; SMN2SLC6A4
SCHEMBL8153873 0.78 L3MBTL1 (0.49) L3MBTL1HTTLMNASMN1; SMN2SLC6A4
SCHEMBL7400584 0.77 CHRM1 (0.65) L3MBTL1LMNASLC6A4HTR2AKCNH2
SCHEMBL10094756 0.76 SLC6A4 (0.37) SMN1; SMN2SLC6A4HTR2AKCNH2MAPT
SCHEMBL9995320 0.76 SLC6A4 (0.52) SLC6A4HTR2AKCNH2MAPTCHRM1
SCHEMBL10093147 0.73 SLC6A4 (0.51) L3MBTL1HTTSLC6A4HTR2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159549-A1 METHOD FOR PREPARATION OF ASENAPINE ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) 2023-05-25 US disclosed
US-20230159549-A1 METHOD FOR PREPARATION OF ASENAPINE ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) 2023-05-25 US disclosed
US-11535628-B2 Method for preparation of Asenapine ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) 2022-12-27 US disclosed
EP-4015519-A1 METHOD OF PREPARING ASENAPINE Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) 2022-06-22 EP disclosed
WO-2021027813-A1 METHOD OF PREPARING ASENAPINE 浙江奥翔药业股份有限公司 2021-02-18 WO disclosed
US-20210047339-A1 METHOD FOR PREPARATION OF ASENAPINE ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) 2021-02-18 US disclosed
EP-2468751-B1 Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole MEDICHEM SA (ES) 2016-03-16 EP disclosed
CN-103760280-A Method for separating and measuring asenapine intermediate related substances by liquid chromatography AVENTIS PHARMA HAINAN CO LTD 2014-04-30 CN disclosed
US-8580972-B2 Processes for the preparation of 5-chloro-2-methyl-2,3,3A,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole MEDICHEM, S.A. (ES) 2013-11-12 US disclosed
US-8580972-B2 Processes for the preparation of 5-chloro-2-methyl-2,3,3A,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole MEDICHEM, S.A. (ES) 2013-11-12 US disclosed
WO-2013024492-A2 A PROCESS FOR THE PREPARATION OF ASENAPINE AND NOVEL SALTS THEREOF MEGAFINE PHARMA (P) LTD. (IN) 2013-02-21 WO disclosed
US-20120165545-A1 PROCESSES FOR THE PREPARATION OF 5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE MEDICHEM, S.A. (ES) 2012-06-28 US disclosed
US-20120165545-A1 PROCESSES FOR THE PREPARATION OF 5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE MEDICHEM, S.A. (ES) 2012-06-28 US disclosed
EP-2468751-A2 Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole Medichem, S.A. (ES) 2012-06-27 EP disclosed
US-20090209608-A1 DEUTERIUM-ENRICHED ASENAPINE PROTIA, LLC (US) 2009-08-20 US disclosed
US-20090209608-A1 DEUTERIUM-ENRICHED ASENAPINE PROTIA, LLC (US) 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159549-A1 METHOD FOR PREPARATION OF ASENAPINE CYP3A5, QDPR, SPR L3MBTL1 4733/4885HTT 1107/4885LMNA 1191/4885
US-11535628-B2 Method for preparation of Asenapine CYP3A5, QDPR, SPR L3MBTL1 4733/4885HTT 1107/4885LMNA 1191/4885
US-20090209608-A1 DEUTERIUM-ENRICHED ASENAPINE NSD2, DRD2, SNRPD2 L3MBTL1 4218/4885HTT 442/4885LMNA 1972/4885
US-20210047339-A1 METHOD FOR PREPARATION OF ASENAPINE CYP3A5, QDPR, SPR L3MBTL1 4733/4885HTT 1107/4885LMNA 1191/4885
US-20120165545-A1 PROCESSES FOR THE PREPARATION OF 5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE DHPS, CYP3A5, ALKBH5 L3MBTL1 4473/4885HTT 2578/4885LMNA 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.